Showing results 1 to 20 of 52
  ESC working group on valvular heart disease position paper-heart valve clinics: organization, structure, and experiencesLANCELLOTTI, Patrizio  ; ; et alin European Heart Journal (2013) Detailed reference viewed: 26 (6 ULg)Left ventricular contractile reserve in asymptomatic primary mitral regurgitationMagne, Julien ; ; PIERARD, Luc et alin European Heart Journal (2013) Detailed reference viewed: 11 (2 ULg)Tricuspid valve regurgitation in patients with heart failure: does it matter?Lancellotti, Patrizio ; Magne, Julien in European Heart Journal (2013) Detailed reference viewed: 17 (2 ULg)2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.; ; et al in European Heart Journal (2012), 33(21), 2719-47 Detailed reference viewed: 11 (2 ULg)European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).; ; et al in European Heart Journal (2012) Detailed reference viewed: 23 (1 ULg)ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.; ; et al in European Heart Journal (2012), 33(20), 2569-619 Detailed reference viewed: 12 (2 ULg)ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.; ; et al in European Heart Journal (2012), 33(14), 1787-847 Detailed reference viewed: 13 (1 ULg)ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).; ; et al in European Heart Journal (2011), 32(23), 2999-3054 Detailed reference viewed: 57 (1 ULg) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).; ; et al in European Heart Journal (2011), 32(14), 1769-818 Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and ... [more ▼] Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat. [less ▲] Detailed reference viewed: 9 (0 ULg)ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).; ; et al in European Heart Journal (2011), 32(22), 2851-906 Detailed reference viewed: 90 (1 ULg)ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).; ; et al in European Heart Journal (2011), 32(23), 2999-3054 Detailed reference viewed: 19 (2 ULg)ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).; ; et al in European Heart Journal (2011), 32(24), 3147-97 Detailed reference viewed: 11 (1 ULg)A moving heartMoonen, Marie ; Davin, Laurent ; Lancellotti, Patrizio et alin European Heart Journal (2010) Detailed reference viewed: 24 (6 ULg)Experience with revascularization procedures does matter: low volume means worse outcome.; Kolh, Philippe in European Heart Journal (2010), 31(16), 1954-7 Detailed reference viewed: 2 (1 ULg)Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).; Kolh, Philippe ; et alin European Heart Journal (2010), 31(20), 2501-55 Detailed reference viewed: 38 (2 ULg)Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment.PIERARD, Luc ; in European Heart Journal (2010), 31 Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents ... [more ▼] Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents the valvular consequences of increased tethering forces (papillary muscles displacement leading to a more apical position of the leaflets and their coaptation point) and reduced closing forces (reduced contractility, dyssynchrony of the papillary muscles, intra-left ventricular dyssynchrony). Although mitral regurgitation has an unloading effect and reduces impedance, the volume overload begets further left ventricular dilatation, increases ventricular wall stress leading to worsened performance. Ischaemic mitral regurgitation is characteristically dynamic: its severity may vary with haemodynamic conditions. Both the severity of ischaemic mitral regurgitation and its dynamic component worsen prognosis. There are numerous possible treatment modalities, but the management of the individual patient remains difficult. Medical therapy is mandatory; revascularization procedures are frequently not sufficient to reduce mitral regurgitation; the role of combined surgical therapy by mitral valve repair is not yet defined in the absence of large randomized trial. Some patients are good candidates for cardiac resynchronization therapy that may reduce the amount of regurgitation. New therapeutic targets are under investigation. [less ▲] Detailed reference viewed: 2 (1 ULg)Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).; ; et al in European Heart Journal (2010), 31(19), 2369-429 Detailed reference viewed: 30 (0 ULg)Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).Pierard, Luc in European Heart Journal (2009), 30(22), 2769-812 Detailed reference viewed: 17 (0 ULg)Stress echocardiography expert consensus statement-executive summary: european association of echocardiography (a registrated branch of the ESC).; ; et al in European Heart Journal (2009), 30(3), 278-89 Detailed reference viewed: 12 (1 ULg)Appropriate myocardial revascularization: a joint viewpoint from an interventional cardiologist and a cardiac surgeon.; Kolh, Philippe in European Heart Journal (2009), 30(18), 2182-5 Detailed reference viewed: 9 (2 ULg) |
||
